These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38860519)

  • 1. Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner.
    Chan JSF; Greenwell AA; Saed CT; Stenlund MJ; Mangra-Bala IA; Tabatabaei Dakhili SA; Yang K; Ferrari SR; Eaton F; Gopal K; Ussher JR
    J Endocrinol; 2024 Aug; 262(2):. PubMed ID: 38860519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.
    Almutairi M; Gopal K; Greenwell AA; Young A; Gill R; Aburasayn H; Al Batran R; Chahade JJ; Gandhi M; Eaton F; Mailloux RJ; Ussher JR
    Can J Cardiol; 2021 Jan; 37(1):140-150. PubMed ID: 32640211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity.
    Gopal K; Al Batran R; Altamimi TR; Greenwell AA; Saed CT; Tabatabaei Dakhili SA; Dimaano MTE; Zhang Y; Eaton F; Sutendra G; Ussher JR
    Cell Rep; 2021 Apr; 35(1):108935. PubMed ID: 33826891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats.
    Cai H; Zhou L; Liu J; Li Z; Chen S
    Biochem Biophys Res Commun; 2022 Nov; 629():112-120. PubMed ID: 36116373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.
    Roumane A; Mcilroy GD; Sommer N; Han W; Heisler LK; Rochford JJ
    Front Endocrinol (Lausanne); 2024; 15():1379228. PubMed ID: 38745956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
    Moffett RC; Patterson S; Irwin N; Flatt PR
    Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined 13C Hyperpolarized Magnetic Resonance and Echocardiography Study.
    Le Page LM; Rider OJ; Lewis AJ; Ball V; Clarke K; Johansson E; Carr CA; Heather LC; Tyler DJ
    Diabetes; 2015 Aug; 64(8):2735-43. PubMed ID: 25795215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy.
    Zhao T; Chen H; Xu F; Wang J; Liu Y; Xing X; Guo L; Zhang M; Lu Q
    Acta Biochim Biophys Sin (Shanghai); 2019 Mar; 51(3):293-300. PubMed ID: 30883649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
    Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
    Filchenko I; Simanenkova A; Chefu S; Kolpakova M; Vlasov T
    Diab Vasc Dis Res; 2018 Nov; 15(6):567-570. PubMed ID: 30024276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats.
    Inoue T; Inoguchi T; Sonoda N; Hendarto H; Makimura H; Sasaki S; Yokomizo H; Fujimura Y; Miura D; Takayanagi R
    Atherosclerosis; 2015 May; 240(1):250-9. PubMed ID: 25818251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R; Almutairi M; Ussher JR
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.
    Helmstädter J; Frenis K; Filippou K; Grill A; Dib M; Kalinovic S; Pawelke F; Kus K; Kröller-Schön S; Oelze M; Chlopicki S; Schuppan D; Wenzel P; Ruf W; Drucker DJ; Münzel T; Daiber A; Steven S
    Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):145-158. PubMed ID: 31747801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glucagon-like peptide-1 receptor agonist liraglutide improves hypoxia-induced pulmonary hypertension in mice partly via normalization of reduced ET(B) receptor expression.
    Honda J; Kimura T; Sakai S; Maruyama H; Tajiri K; Murakoshi N; Homma S; Miyauchi T; Aonuma K
    Physiol Res; 2018 Jun; 67(Suppl 1):S175-S184. PubMed ID: 29947538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac-Specific Deletion of Pyruvate Dehydrogenase Impairs Glucose Oxidation Rates and Induces Diastolic Dysfunction.
    Gopal K; Almutairi M; Al Batran R; Eaton F; Gandhi M; Ussher JR
    Front Cardiovasc Med; 2018; 5():17. PubMed ID: 29560354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
    Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
    Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment.
    Wang L; Li P; Tang Z; Yan X; Feng B
    Sci Rep; 2016 Sep; 6():33251. PubMed ID: 27633081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide Effect on Ventricular Transient Outward K +  Channel and Connexin-43 Protein Expression.
    Ramadan NM; Malek HA; Rahman KA; El-Kholy E; Shaalan D; Elkashef W
    Exp Clin Endocrinol Diabetes; 2021 Dec; 129(12):899-907. PubMed ID: 32559789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.